EyePoint Pharmaceuticals

Watertown, United States Founded: 1987 • Age: 39 yrs Listed Acquired By pSivida
Small molecule therapeutics for ophthalmic disorders are developed.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals is a publicly listed company based in Watertown (United States) founded in 1987, and was acquired by pSivida in March 2018. Small molecule therapeutics for ophthalmic disorders are developed. The company has 165 employees. EyePoint Pharmaceuticals has completed 2 acquisitions, including Contractordeliverysystems and Icon Bioscience. EyePoint Pharmaceuticals offers products and services including DURAVYUâ„¢ and Durasert Eâ„¢. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is PSIVIDA CORP. Its competitors include Rezolute, Aviceda Therapeutics and IVERIC bio; 2 of its 3 listed competitors have raised funding.

Company details

EyePoint Pharmaceuticals was founded in 1987 and is headquartered in Watertown, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics for ophthalmic disorders are developed. A proprietary Durasert technology is employed, consisting of a miniaturized, injectable, sustained-release drug delivery system for small molecules. Lead candidates include Yutiq, targeted at chronic non-infectious uveitis, and EYEP-1901, addressed to wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.

  • Headquarters Watertown, United States
  • Employees 165
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website eyepointpharma.com
  • Social LinkedIn X Facebook
  • Acquired by pSivida (Mar 2018)
  • Legal Name Eyepoint Pharmaceuticals, Inc.
Operational Areas
Key Metrics
  • Annual Revenue
    $31.37 M (USD)
    -27.5
    as on Dec 31, 2025
  • Net Profit
    -$231.96 M (USD)
    -77.25
    as on Dec 31, 2025
  • EBITDA
    -$241.13 M (USD)
    -67.08
    as on Dec 31, 2025
  • Latest Funding Round
    $15.7M (USD), Post-IPO

    Jan 2021

  • Investors
    pSivida

    & 5 more

  • Employee Count
    165
  • Investments & Acquisitions
  • Acquired by
    pSivida

    (Mar 2018)

Products & Services of EyePoint Pharmaceuticals

EyePoint Pharmaceuticals offers a comprehensive portfolio of products and services, including DURAVYU™ and Durasert E™.

DURAVYU™
Therapeutic

Investigational treatment for VEGF mediated retinal diseases.

Durasert E™
Delivery Technology

Proprietary system for sustained intraocular drug delivery.

Funding Insights of EyePoint Pharmaceuticals

  • Total Rounds 5
  • Last Round Post-IPO — $15.7M
  • First Round $20M

    (Mar 2018)

  • Investors Count 5

All 5 funding rounds of EyePoint Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2021$15.7MPost-IPO––
Feb 2019$60MDebt – Conventional––
Oct 2018$28.9MPost-IPO––
Mar 2018$20MDebt – Conventional––
Mar 2018$9.92MPost-IPO––
Valuation history

6 investors in total: 6 institutional.

Investors in EyePoint Pharmaceuticals

EyePoint Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include pSivida, OcuMension and SWK Holdings.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
CRG is recognized as a premier healthcare investment partner.
crglp.comHouston, United States
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
ewhealthcare.comNew York, United States
Ophthalmic drugs for eye disorders are developed.
2017ocumension.comShanghai, China
Provides investment management for life sciences and biotech funds to investors worldwide.
2006rosalindcap.comToronto, Canada
Investments and advisory services are provided by the holding company.
2009swkhold.comDallas, United States
Drug delivery systems
1987psivida.comWatertown, United States
Premium access

Investor details for EyePoint Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

IPO & Listings of EyePoint Pharmaceuticals

EyePoint Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol EYPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Dec 2020
  • Listed onFRA: PV3B
  • Listed entityEyePoint Pharmaceuticals, Inc.
  • Exchange sectorHealth technology
  • ISINUS30233G2093
  • Share price$3.07 (-7.53% on the day) · 2026-10-13
  • Market capitalisation$264.7M
  • EPS (diluted, trailing year)$-3.74
  • Volume (last session)2,515,785

Financials of EyePoint Pharmaceuticals

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$31.4M-$232.0M-$241.1M
2024$43.3M-$130.9M-$144.3M
2023$46.0M-$70.8M-$73.2M
2022$41.4M-$102.2M-$76.5M
2021$36.9M-$58.4M-$52.5M
Premium access

Detailed financial statements for EyePoint Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by EyePoint Pharmaceuticals

EyePoint Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Contractordeliverysystems and Icon Bioscience.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Online pharmacy providing prescription drugs and other health products
iconbioscience.comSunnyvale, United States2004Mar 2018••••
Provider of commercial construction services including concrete, painting, and tenant finish
contractordeliverysystems.com0Oct 2005$104M
Premium access

Complete acquisition details for EyePoint Pharmaceuticals

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of EyePoint Pharmaceuticals

7 dated milestones of EyePoint Pharmaceuticals across 34 years, from founding to its latest funding, stage changes and deals.

  1. Founded EyePoint Pharmaceuticals is founded.
  2. Acquisition Acquires Contractordeliverysystems.
  3. Funding First funding round of $20.0M.
  4. Acquisition Acquires Icon Bioscience.
  5. Exit Acquired by pSivida.
  6. IPO Lists on the stock exchange (IPO).
  7. Funding Latest funding round, Post-IPO, of $15.7M.

Competitors of EyePoint Pharmaceuticals

EyePoint Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Rezolute, Aviceda Therapeutics and IVERIC bio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
rezolutebio.com2012Denver, United States51
Therapies for metabolic and orphan diseases are developed by Rezolute.
avicedarx.com2018Cambridge, United States$254.66M
Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas.
ivericbio.com2007New York, United States$206.77M94
Gene therapy solutions for retinal diseases are developed.
Premium access

Detailed competitors of EyePoint Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of EyePoint Pharmaceuticals

The website of EyePoint Pharmaceuticals (eyepointpharma.com) receives about 3.9K visits a month and ranks #3,819,866 among all websites worldwide, #4,875 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3.9K

    ▼ 24.4% vs previous month

  • Unique visitors
    2.2K

    per month

  • Global rank
    #3,819,866

    among all websites

  • Category rank
    #4,875

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with EyePoint Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
cocrystalpharma.com
100%
2.9K#6,117,909View details
empr.com
empr.com
60%
#153,602–

Top companies in Ophthalmology

3 companies that operate in the same segment as EyePoint Pharmaceuticals (Ophthalmology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of a wide range of eye care products
1945Fort Worth, Texas, United StatesUSD 171.61 MUSD 24.69 B25,941
Genetic medicines are developed by 4DMT for transformative therapies.
2013Emeryville, California, United StatesUSD 186.59 MUSD 85.21 M227
Developer of antibodies to treat complement-mediated neurodegenerative diseases
2011San Francisco, California, United StatesUSD 256 M100
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Eyepoint Pharmaceuticals

Premium access

Complete news archive for EyePoint Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about EyePoint Pharmaceuticals

EyePoint Pharmaceuticals was founded in 1987 and raised its 1st funding round 31 years after it was founded.

EyePoint Pharmaceuticals is headquartered in Watertown, United States.

EyePoint Pharmaceuticals has 165 employees.

Annual revenue of EyePoint Pharmaceuticals is $31.37M as on Dec 31, 2025.

EyePoint Pharmaceuticals was founded in 1987 and is headquartered in Watertown, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics for ophthalmic disorders are developed. A proprietary Durasert technology is employed, consisting of a miniaturized, injectable, sustained-release drug delivery system for small molecules. Lead candidates include Yutiq, targeted at chronic non-infectious uveitis, and EYEP-1901, addressed to wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.

EyePoint Pharmaceuticals's top competitors include Rezolute, Aviceda Therapeutics and IVERIC bio.

EyePoint Pharmaceuticals offers DURAVYUâ„¢ and Durasert Eâ„¢.

Yes, EyePoint Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol EYPT.

EyePoint Pharmaceuticals has made 2 acquisitions, including Contractordeliverysystems, and Icon Bioscience.

EyePoint Pharmaceuticals has 6 investors. Key investors include pSivida, OcuMension, SWK Holdings, CRG, and EW Healthcare Partners.

EyePoint Pharmaceuticals operates through Psivida Corp..

Yes. EyePoint Pharmaceuticals was acquired by pSivida in March 2018.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available